home / stock / vigl / vigl articles
WATERTOWN, Mass. , Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to ...
Vigil Neuroscience Inc (NASDAQ: VIGL) shares are down after the company released interim data from its Phase 2 IGNITE proof-of-concept clinica...
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite falling around 30 points on Friday. Following the market opening Friday, ...
JMP Securities has initiated coverage on Vigil Neuroscience Inc (NASDAQ: VIGL), noting the company's focus on neurodegenerative ...
Gainers Applied UV, Inc. (NASDAQ: AUVI) gained 60.4% to $0.4924. Applied UV said its new product, the Airocide® Pro+ air purification system f...
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to ...
WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to...
News, Short Squeeze, Breakout and More Instantly...
Vigil Neuroscience Inc. Company Name:
VIGL Stock Symbol:
NASDAQ Market:
Vigil Neuroscience Inc. Website:
2024-06-28 09:15:05 ET Wedbush analyst issues OUTPERFORM recommendation for VIGL on June 28, 2024 07:53AM ET. The previous analyst recommendation was Outperform. VIGL was trading at $4.48 at issue of the analyst recommendation. Historical Analyst Recommendations La...
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2 agonist program, including VG-3927, currently in phase 1 clinical studies - ...